Remove 2025 Remove Networking Remove Patients
article thumbnail

Top Challenges for Pharma Marketing in 2025

Pharma Marketing Network

The world of pharma marketing is changing rapidly, and 2025 will be no exception. So, what will be the top challenges in 2025, and how can pharma marketers tackle them? This shift includes everything from leveraging social media to engaging patients through apps and personalized email campaigns.

article thumbnail

Healthcare CNO Summit 2025: Uniting Leaders in Nursing for Innovation and Collaboration

PM360

The 2025 Healthcare CNO Summit , an exclusive invitation-only event, is scheduled for February 3-4, 2025, at The Ritz-Carlton Dallas, Las Colinas. Quality Safety Controls: Mitigating challenges to ensure patient safety and quality care.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Power of Healthcare Branding: Strategies for Pharma Marketing Success in 2025

Pharma Marketing Network

As we approach 2025, the ability of pharmaceutical companies to effectively craft and communicate their brand identity will play a pivotal role in determining their market success. Key Strategies for Pharma Marketing in 2025 As pharmaceutical companies look to 2025, embracing a patient-centric approach will be pivotal.

article thumbnail

op Pharma Marketing Trends Shaping the Future of Healthcare in 2025

Pharma Marketing Network

As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. As patients become more digitally savvy, pharma companies are investing in creating seamless digital experiences that cater to their needs and preferences.

article thumbnail

Making ATMPs a reality for rare disease patients

European Pharmaceutical Review

The implementation of the EU’s Health Technology Assessment Regulation (HTAR) 1 will play a key role in shaping the patient access pathway for ATMPs such as cell and gene therapies. Currently, these therapies primarily target rare or ultra-rare diseases with small patient populations, which therefore limits clinical study sizes.

article thumbnail

Highlights from The Data Ecosystem in 2025

Prognos Health

This in-person event brought healthcare leaders together to discuss emerging opportunities and challenges around the use of health data to improve patient outcomes. More data should uncover more info about the patient. This includes clinical sensors and devices providing patient-generated data.

article thumbnail

Big Data Steering Group to enhance data quality and discoverability under new workplan

European Pharmaceutical Review

The joint Big Data Steering Group of the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) has published a third workplan, setting actions to be delivered by 2025. According to EMA, the new plan will further enhance the efficient integration of data analysis into the regulatory evaluation of medicinal products.

Medicine 105